While 4D Molecular Therapeutics Inc has overperformed by 0.59%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FDMT fell by -15.22%, with highs and lows ranging from $36.25 to $8.37, whereas the simple moving average fell by -59.87% in the last 200 days.
On September 23, 2024, Cantor Fitzgerald Downgraded 4D Molecular Therapeutics Inc (NASDAQ: FDMT) to Neutral. A report published by Barclays on April 15, 2024, Initiated its previous ‘Overweight’ rating for FDMT. Barclays also rated FDMT shares as ‘Overweight’, setting a target price of $45 on the company’s shares in an initiating report dated April 15, 2024. Goldman Initiated an Buy rating on February 07, 2024, and assigned a price target of $81. RBC Capital Mkts initiated its ‘Outperform’ rating for FDMT, as published in its report on October 26, 2023. Cantor Fitzgerald’s report from October 24, 2023 suggests a price prediction of $32 for FDMT shares, giving the stock a ‘Overweight’ rating. Leerink Partners also rated the stock as ‘Outperform’.
Analysis of 4D Molecular Therapeutics Inc (FDMT)
Further, the quarter-over-quarter decrease in sales is -98.32%, showing a negative trend in the upcoming months.
4D Molecular Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -33.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 28.48, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and FDMT has an average volume of 872.41K. On a monthly basis, the volatility of the stock is set at 4.89%, whereas on a weekly basis, it is put at 3.86%, with a loss of -4.98% over the past seven days. Furthermore, long-term investors anticipate a median target price of $50.00, showing growth from the present price of $8.58, which can serve as yet another indication of whether FDMT is worth investing in or should be passed over.
How Do You Analyze 4D Molecular Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.84%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 105.44% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
FDMT shares are owned by institutional investors to the tune of 105.44% at present.
